Advertisement

Cancer stem cells: Opportunities for novel diagnostics and drug discovery

  • W. Nicol Keith
    Correspondence
    Tel.: +44 141 330 4811; fax: +44 141 330 4127.
    Affiliations
    Centre for Oncology & Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK
    Search for articles by this author
      This special issue of the European Journal of Cancer focuses on the cancer stem cell and comprises a wide spectrum of excellent articles. Over the past five years, we have seen a steady rise in publication activity in this subject area (Fig. 1) and it seems appropriate to take stock of where we are in this rapidly emerging field. This is a topic of considerable interest to both clinical and experimental oncologists and the collection of review articles covers aspects of cancer stem cells ranging from clinical issues, such as new therapies, through to cell signalling and model systems (Fig. 2).
      Figure thumbnail gr1
      Fig. 1Publication activity in the subject area of cancer stem cells over the 5-year-period 2001–2005. As an indication of activity in the field, the phrase ‘cancer stem cells’ was used to search PubMed. The graph indicates the number of publications per year.
      Figure thumbnail gr2
      Fig. 2Converging themes in cancer stem cell research covered in this special issue of the European Journal of Cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keith W.N.
        • Bilsland A.
        • Hardie M.
        • Evans T.R.J.
        Cancer cell immortality – telomerase as a target for novel cancer gene therapies.
        Nature Clin Pract Oncol. 2004; 1: 88-96
        • Al-Hajj M.
        • Clarke M.F.
        Self-renewal and solid tumor stem cells.
        Oncogene. 2004; 23: 7274-7282
        • Glinsky G.V.
        • Berezovska O.
        • Glinskii A.B.
        Microarray analysis identifies a death-from cancer signature predicting therapy failure in patients with multiple types of cancer.
        J Clin Invest. 2005; 115: 1503-1521
        • Hirschmann-Jax C.
        • Foster A.E.
        • Wulf G.G.
        • et al.
        A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells.
        Proc Natl Acad Sci USA. 2004; 101: 14228-14233
        • Jones R.J.
        • Matsui W.H.
        • Smith B.D.
        Cancer stem cells: are we missing the target?.
        J Natl Cancer Inst. 2004; 96: 583-585
        • Keith W.N.
        From stem cells to cancer: balancing immortality and neoplasia.
        Oncogene. 2004; 23: 5095-5098
        • Serakinci N.
        • Guldberg P.
        • Burns J.
        • et al.
        Adult human mesenchymal stem cell as a target for neoplastic transformation.
        Oncogene. 2004; 23: 5092-5094
        • Singh S.K.
        • Clarke I.D.
        • Hide T.
        • Dirks P.B.
        Cancer stem cells in nervous system tumors.
        Oncogene. 2004; 23: 7267-7273